The drug, semaglutide, works by hijacking the body’s own appetite-regulating system in the brain, resulting in reduced hunger and calorie intake, according to a study published Thursday in the ‘New England Journal for Medicine. ‘.
A third (35%) of people who took the new drug to treat obesity lost more than a fifth of their total body weight, according to the large global study involving researchers at University College London (UCL) and nearly 2,000 trial participants in 16 of the countries.
“The results of this study represent a major breakthrough in improving the health of obese people. Three-quarters (75%) of people who received 2.4 mg of semaglutide lost more than 10% of their body weight and more than a third lost more than 20 percent, ”said lead author Rachel Batterham , professor of obesity, diabetes and endocrinology who directs the Center for Obesity Research at UCL and the UCLH Center for Weight Management.
“No other drug has succeeded in producing this level of weight loss – it is a real game changer. For the first time, people can achieve with drugs what was only possible with bariatric surgery,” said she declared.
The average trial participant lost 15.3 kg; this was accompanied by a reduction in risk factors for heart disease and diabetes, such as waist circumference, blood lipids, blood sugar and blood pressure, and signaled improvements in their overall quality of life.
“The impact of obesity on health has been highlighted by COVID-19, where obesity dramatically increases the risk of dying from the virus, as well as the risk of many serious life-limiting illnesses, including heart disease. , type 2 diabetes, liver disease and certain types of cancers.
This drug could have major implications for UK health policy for years to come, ”added Professor Batterham.
The UK’s chief investigator for the trial, Professor John Wilding of the University of Liverpool, said semaglutide is already approved and clinically used at a lower dose for the treatment of diabetes, so doctors know already in use.
“So it’s good to see this translate into effective treatment for people who are obese,” he said.
With evidence from the international trial, semaglutide has been submitted for regulatory approval as a treatment for obesity to the UK’s National Institute of Clinical Excellence (NICE), the European Medicines Agency (EMA) and to the United States Food and Drug Administration (FDA).
The international trial was funded by pharmaceutical company Novo Nordisk.
7 workout accessories to help you reach your home fitness goals
With the Covid-19 outbreak and the subsequent closure of most public spaces, including gyms, staying in shape has become a challenge. However, with the right motivation and determination, this time at home provides you with the perfect opportunity to focus on your health and fitness, and achieve the bodily goals you’ve always wanted. Plus, exercising will help you feel happy and keep your mind healthy.
To help you get started with a home workout routine, here is a list of the workout accessories you need for a good home workout routine.